Intellia Therapeutics (NTLA) Retained Earnings (2015 - 2026)
Intellia Therapeutics (NTLA) reported Retained Earnings of -$240000.0 for Q1 2026, up 99.99% year-over-year from -$120006.3 in Q1 2025, and down 123.26% on a QoQ basis from $1.0 million in Q4 2025.
Intellia Therapeutics (NTLA) has 12 years of Retained Earnings data on file, last reported at -$240000.0 in Q1 2026.
- Quarterly Retained Earnings rose 99.99% year-over-year to -$240000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$240000.0 (up 99.99% YoY) and the FY2025 annual result came in at $1.0 million, up 70.58% from the prior year.
- Retained Earnings slipped to -$240000.0 in Q1 2026 per NTLA's latest filing, from $1.0 million in the prior quarter.
- Across five years, Retained Earnings topped out at $1.0 million in Q4 2025 and bottomed at -$2.5 billion in Q3 2025.
- The 5-year median for Retained Earnings is -$1.2 billion (2022), against an average of -$1.1 billion.
- The widest annual swing landed in 2022, when Retained Earnings plunged 611267.82%; it then jumped 126.79% in 2024.
- Tracing NTLA's Retained Earnings over 5 years: stood at -$1.2 billion in 2022, then surged by 99.81% to -$2.3 million in 2023, then jumped by 126.79% to $605000.0 in 2024, then surged by 70.58% to $1.0 million in 2025, then slumped by 123.26% to -$240000.0 in 2026.
- Per Business Quant, the three latest NTLA Retained Earnings figures stand at -$240000.0 (Q1 2026), $1.0 million (Q4 2025), and -$2.5 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | -240,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -240,000.00 |
| Dec 31, 2025 | 1.03 Mn |
| Sep 30, 2025 | -2.49 Bn |
| Jun 30, 2025 | -2.39 Bn |
| Mar 31, 2025 | -2.29 Bn |
| Dec 31, 2024 | 605,000.00 |
| Sep 30, 2024 | -2.05 Bn |
| Jun 30, 2024 | -1.91 Bn |
| Mar 31, 2024 | -1.77 Bn |
| Dec 31, 2023 | -2.26 Mn |
| Sep 30, 2023 | -1.53 Bn |
| Jun 30, 2023 | -3.87 Mn |
| Mar 31, 2023 | -1.28 Bn |
| Dec 31, 2022 | -1.18 Bn |
| Sep 30, 2022 | -1.06 Bn |
| Jun 30, 2022 | -950.55 Mn |
| Mar 31, 2022 | -8.06 Mn |
| Dec 31, 2021 | -2.63 Mn |
| Sep 30, 2021 | -174,000.00 |
| Jun 30, 2021 | -550.12 Mn |
| Mar 31, 2021 | -12,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Sep 30, 2020 | -392.92 Mn |
| Jun 30, 2020 | 155,000.00 |
| Mar 31, 2020 | -332.68 Mn |
| Dec 31, 2019 | 261,000.00 |
| Sep 30, 2019 | 336,000.00 |
| Jun 30, 2019 | 255,000.00 |
| Mar 31, 2019 | -223.29 Mn |
| Dec 31, 2018 | -201.03 Mn |
| Sep 30, 2018 | -181.96 Mn |
| Jun 30, 2018 | -159.26 Mn |
| Mar 31, 2018 | -137.04 Mn |
| Dec 31, 2017 | -121.11 Mn |
| Sep 30, 2017 | -97.15 Mn |
| Jun 30, 2017 | -81.79 Mn |
| Mar 31, 2017 | -66.20 Mn |
| Dec 31, 2016 | -53.57 Mn |
| Sep 30, 2016 | -43.01 Mn |
| Jun 30, 2016 | -35.53 Mn |
| Mar 31, 2016 | -28.63 Mn |
| Dec 31, 2015 | -21.94 Mn |